Biological Activity Profiles of Multitarget Ligands from X-ray Structures
暂无分享,去创建一个
[1] Renxiao Wang,et al. The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.
[2] Jürgen Bajorath,et al. Entering the ‘big data’ era in medicinal chemistry: molecular promiscuity analysis revisited , 2017, Future science OA.
[3] Julio Saez-Rodriguez,et al. BioServices: a common Python package to access biological Web Services programmatically , 2013, Bioinform..
[4] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[5] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[6] Jürgen Bajorath,et al. Promiscuity of inhibitors of human protein kinases at varying data confidence levels and test frequencies , 2017 .
[7] Sameer Velankar,et al. PDBe: Protein Data Bank in Europe , 2009, Nucleic Acids Res..
[8] Ian A. Watson,et al. Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.
[9] Jameed Hussain,et al. Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..
[10] Jürgen Bajorath,et al. X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design , 2018, ACS omega.
[11] Kenneth M Merz,et al. The Ecstasy and Agony of Assay Interference Compounds. , 2017, ACS chemical neuroscience.
[12] Christoph Steinbeck,et al. ChEBI in 2016: Improved services and an expanding collection of metabolites , 2015, Nucleic Acids Res..
[13] Jürgen Bajorath,et al. Determining the Degree of Promiscuity of Extensively Assayed Compounds , 2016, PloS one.
[14] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[15] Zukang Feng,et al. The Protein Data Bank and structural genomics , 2003, Nucleic Acids Res..
[16] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[17] Yanli Wang,et al. PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..
[18] A. Cavalli,et al. Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.
[19] J. Irwin,et al. An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.
[20] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[21] Jürgen Bajorath,et al. Identifying Promiscuous Compounds with Activity against Different Target Classes , 2019, Molecules.
[22] Sameer Velankar,et al. PDBe: Protein Data Bank in Europe , 2009, Nucleic Acids Res..
[23] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[24] M L Bolognesi,et al. Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.